BioCardia (NASDAQ:BCDA – Get Free Report) and Atyr PHARMA (NASDAQ:ATYR – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.
Insider & Institutional Ownership
20.6% of BioCardia shares are held by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are held by institutional investors. 20.0% of BioCardia shares are held by insiders. Comparatively, 3.7% of Atyr PHARMA shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk and Volatility
BioCardia has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| BioCardia | -1,999.77% | N/A | -208.38% |
| Atyr PHARMA | N/A | -79.44% | -59.16% |
Valuation and Earnings
This table compares BioCardia and Atyr PHARMA”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioCardia | $71,000.00 | 139.46 | -$11.57 million | ($4.19) | -0.52 |
| Atyr PHARMA | $235,000.00 | 1,168.04 | -$50.39 million | ($0.94) | -3.48 |
BioCardia has higher earnings, but lower revenue than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and price targets for BioCardia and Atyr PHARMA, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioCardia | 0 | 0 | 1 | 0 | 3.00 |
| Atyr PHARMA | 0 | 0 | 4 | 0 | 3.00 |
BioCardia presently has a consensus price target of $25.00, indicating a potential upside of 1,057.41%. Atyr PHARMA has a consensus price target of $19.25, indicating a potential upside of 488.69%. Given BioCardia’s higher possible upside, equities research analysts clearly believe BioCardia is more favorable than Atyr PHARMA.
Summary
Atyr PHARMA beats BioCardia on 7 of the 13 factors compared between the two stocks.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
About Atyr PHARMA
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
